{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-180754","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2024-07-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.230185+00:00","generated_at":"2026-05-31T19:52:51.465911+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"NewAmsterdam appoints McKenna and Joustra to board; Slootweg resigns","bullets":["Sander Slootweg resigned from the Board effective July 16, 2024; no disagreement cited.","Wouter Joustra (Forbion general partner) and Mark C. McKenna (Mirador CEO) appointed as temporary non-executive directors.","McKenna granted options for 72,500 ordinary shares at $18.81 per share, vesting over 3 years.","McKenna also joins audit and compensation committees; Joustra brings capital markets and venture experience.","Appointments effective immediately; formal ratification expected at next annual general meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-180754","json":"https://secwatch.observer/filing/0001193125-24-180754.json","markdown":"https://secwatch.observer/filing/0001193125-24-180754.md","text":"https://secwatch.observer/filing/0001193125-24-180754.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524180754/0001193125-24-180754-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524180754/d744813d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T19:52:51.465911+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"66dabdce6b","claim":"Sander Slootweg resigned as Director at NewAmsterdam Pharma Co N.V..","evidence_excerpt":"On July 16, 2024, Sander Slootweg notified NewAmsterdam Pharma Company N.V. (the “Company”) of his decision to resign as a member of the Company’s board of directors (the “Board”) effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524180754/0001193125-24-180754-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"6ebd12fd98","claim":"Wouter Joustra was appointed as Director at NewAmsterdam Pharma Co N.V..","evidence_excerpt":"On July 16, 2024, the Board appointed Wouter Joustra and Mark C. McKenna to serve as members of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524180754/0001193125-24-180754-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d035800fa9","claim":"Mark C. McKenna was appointed as Director at NewAmsterdam Pharma Co N.V..","evidence_excerpt":"On July 16, 2024, the Board appointed Wouter Joustra and Mark C. McKenna to serve as members of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524180754/0001193125-24-180754-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}